Caplin Point Reports Strong Q2 FY27 With Solid Revenue and PAT Growth
Caplin Point Laboratories Ltd · Investor Presentation · 12 Nov 2026, 6:51 pm
Caplin Point Reports Strong Q2 FY27 With Solid Revenue and PAT Growth Caplin Point Laboratories reported consolidated Q2 FY27 revenue from operations of ₹629.84 Cr, up 17.9% YoY (3.2% QoQ), while net profit grew 13.8% YoY to ₹182.35 Cr with a 27.5% PAT margin. EBITDA stood at ₹256.51 Cr, up 16.8% YoY with margins at 38.7%. For H1 FY27, revenue reached ₹1,240.20 Cr (+18.8% YoY) and PAT reached ₹361.42 Cr (+16.2% YoY). The balance sheet remains debt-free with free cash reserves of ₹1,534 Cr, funding an ongoing ₹1,000+ Cr capex plan entirely through internal accruals.
Original exchange filing (PDF)
More announcements from Caplin Point Laboratories Ltd
- Classification of US FDA Inspection at the facility of Caplin Steriles Limited, subsidiary of the Company as OAI · 17 Nov 2026
- Audio Recording of Earnings call for the Quarter and half year ended September 30, 2026 · 13 Nov 2026
- Financial Results for the quarter and half year ended September 30, 2026 · 12 Nov 2026
- Board Meeting Outcome for Meeting Held on November 12, 2026 · 12 Nov 2026
- Caplin Point Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 12 Nov 2026
- Analyst / investor Call for the quarter and half ended September 30, 2026 · 12 Nov 2026
- CAPLIN POINT LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 12-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 12 Nov 2026
- To consider and approve the financial results for the period ended September 30, 2026 · 12 Nov 2026
